4.8 Article

Accurate quantification of DNA methylation using combined bisulfite restriction analysis coupled with the Agilent 2100 Bioanalyzer platform

期刊

NUCLEIC ACIDS RESEARCH
卷 34, 期 3, 页码 -

出版社

OXFORD UNIV PRESS
DOI: 10.1093/nar/gnj017

关键词

-

资金

  1. NCI NIH HHS [CA110496, P01 CA081534, CA93548, CA-081534, R21 CA110496, R01 CA093548] Funding Source: Medline
  2. NIDCR NIH HHS [R01 DE013123, DE013123] Funding Source: Medline
  3. NATIONAL CANCER INSTITUTE [R01CA093548, P20CA081534, P01CA081534, R21CA110496] Funding Source: NIH RePORTER
  4. NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013123] Funding Source: NIH RePORTER

向作者/读者索取更多资源

DNA methylation is the best-studied epigenetic modification and describes the conversion of cytosine to 5-methylcytosine. The importance of this phenomenon is that aberrant promoter hypermethylation is a common occurrence in cancer and is frequently associated with gene silencing. Various techniques are currently available for the analysis of DNA methylation. However, accurate and reproducible quantification of DNA methylation remains challenging. In this report, we describe Bio-COBRA (combined bisulfite restriction analysis coupled with the Agilent 2100 Bioanalyzer platform), as a novel approach to quantitative DNA methylation analysis. The combination of a well-established method, COBRA, which interrogates DNA methylation via the restriction enzyme analysis of PCR-amplified bisulfite treated DNAs, with the Bioanalyzer platform allows for the rapid and quantitative assessment of DNA methylation patterns in large sample sets. The sensitivity and reproducibility of Bio-COBRA make it a valuable tool for the analysis of DNA methylation in clinical samples, which could aid in the development of diagnostic and prognostic parameters with respect to disease detection and management.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据